Aktie
MABVAX THERAP. HLDGS Kennzahlen
- WKN
- A2JEE4
- ISIN
- US55414P7024
- Ticker
- TK8R
- WKN
- A2JEE4
- Ticker
- TK8R
- ISIN
- US55414P7024
Fundamentale Kennzahlen
| Gewinn | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gewinn pro Aktie in EUR | – | – | – | – | – | – | – | – | – | – | – | – | – |
KGV | – | – | – | – | – | – | – | – | – | – | – | – | – |
Gewinnwachstum (%) | – | – | – | – | – | – | – | – | – | – | – | – | – |
PEG | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Dividende | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dividende in EUR | – | – | – | – | – | – | – | – | – | – | – | – | – |
Dividendenrendite (%) | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Cashflow | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cashflow je Aktie in EUR | – | – | – | – | – | – | – | – | – | – | – | – | – |
Kurs-Cashflow-Verhältnis (KCV) | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Umsatz | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Umsatz in | – | – | – | – | – | – | – | – | – | – | – | – | – |
Umsatzwachstum (%) | – | – | – | – | – | – | – | – | – | – | – | – | – |
Umsatz je Mitarbeiter in EUR | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Buchwert | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Buchwert je Aktie in EUR | – | – | – | – | – | – | – | – | – | – | – | – | – |
Kurs-Buch-Verhältnis (KBV) | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Bilanz | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bilanzsumme in | – | – | – | – | – | – | – | – | – | – | – | – | – |
Eigenkapitalquote (%) | – | – | – | – | – | – | – | – | – | – | – | – | – |
Verschuldungsgrad (%) | – | – | – | – | – | – | – | – | – | – | – | – | – |
dyn. Verschuldungsgrad (%) | – | – | – | – | – | – | – | – | – | – | – | – | – |
Bilanzierungsmethode | – | – | – | – | – | – | – | – | – | – | – | – | – |
Geschäftsjahresende | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Marktkapitalisierung | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Marktkapitalisierung in EUR | – | – | – | – | – | – | 45.261,99 | 65.064,12 | 805.148,63 | 12,17 Mio. | 17,97 Mio. | 16,42 Mio. | 3,34 Mio. |
Marktkapitalisierung/Umsatz | – | – | – | – | – | – | – | – | – | – | – | – | – |
Marktkapitalisierung/Mitarbeiter in EUR | – | – | – | – | – | – | – | – | – | – | – | – | – |
Marktkapitalisierung/EBITDA | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Rentabilität (%) | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cashflow-Marge | – | – | – | – | – | – | – | – | – | – | – | – | – |
EBIT-Marge | – | – | – | – | – | – | – | – | – | – | – | – | – |
EBITDA-Marge | – | – | – | – | – | – | – | – | – | – | – | – | – |
Eigenkapitalrendite | – | – | – | – | – | – | – | – | – | – | – | – | – |
Gesamtkapitalrendite | – | – | – | – | – | – | – | – | – | – | – | – | – |
Cashflow / ROI | – | – | – | – | – | – | – | – | – | – | – | – | – |
Steuerquote | – | – | – | – | – | – | – | – | – | – | – | – | – |
Die geschätzten Kennzahlen werden von FactSet bereitgestellt: Copyright © 2024 FactSet Research Systems Inc. All rights reserved.
Technische Kennzahlen zu MABVAX THERAP. HLDGS
| Risiko- und Trendkennzahlen | |
|---|---|
Gl. Durchschn. - 20T | – |
Gl. Durchschn. - 30T | – |
Gl. Durchschn. - 100T | – |
Gl. Durchschn. - 200T | – |
RSL - 30T | – |
RSL - 250T | – |
Vola - 30T | – |
Vola - 250T | – |
Momentum - 30T | – |
Momentum - 250T | – |
| Performance- und Kurs-Kennzahlen | |||||
|---|---|---|---|---|---|
| Zeitraum | Performance | Hoch | Abstand | Tief | Abstand |
| 1 Woche | – | – | – | – | – |
| 1 Monat | – | – | – | – | – |
| 6 Monate | – | – | – | – | – |
| 1 Jahr | – | – | – | – | – |
| 3 Jahre | – | – | – | – | – |
| 5 Jahre | – | – | – | – | – |
| 7 Jahre | – | – | – | – | – |
| 10 Jahre | – | – | – | – | – |